Abstract: The invention relates to a method for operating a lighting control console (01) for controlling a lighting system, wherein digital adjusting commands are generated in the lighting control console (01), which can be transferred to the lighting devices of the lighting system via data connections, and wherein the lighting control console (01) comprises at least one digital processor and at least one digital memory for generating, managing and storing the adjusting commands, and wherein the lighting control console (01) comprises at least one display device (09), and wherein a color palette for the selection of a color can be graphically represented at the display device (09) for the user; and wherein the display device (09) has a touch-sensitive sensor surface, which by means of touching the same within the region of a contact surface allows for the selection of the digital color parameters of a color from the displayed color palette, including the following method steps: a) Selecting a digital color image (10)

Abstract: Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorders are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round of administration.

Abstract: The present invention is directed to methods of isolating and purifying protein from a bioreactor process. The invention relates to employing a protein phase separation methodology to isolate or purify protein product in the forms of solid, semi-solid, or suspension during a protein manufacturing purification process as a stable storage intermediate. This approach is designed to allow the isolated protein product (purified or partially purified) to be stored over an extended period of time prior to further protein purification steps.

Abstract: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.

Abstract: The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder.

Abstract: This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist.

Abstract: Embodiments of the present invention encompass novel receptors of the TNF family. In particular, embodiments of the invention encompass TNF Receptor in the BRAIN (TRAIN) and isolated antibodies that bind to the same. In some embodiments, isolated antibodies that bind to TRAIN are useful in regulating cell differentiation, death, and survival. Other embodiments of the invention encompass pharmaceutical compositions comprising antibodies that bind to human TRAIN.

Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.

Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).

Abstract: Biomarkers of multiple sclerosis (MS) and of anti-TWEAK/TWEAK-Receptor therapy for MS are described.

Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.

Abstract: Methods of treating cancer using an agent that blocks interaction between TWEAK and its receptor are described.

Abstract: A lighting control console for controlling a lighting control system including a digital processor and a digital storage unit. The lighting control console can comprise several control elements, in particular keys, linear regulators and/or induction regulators, which are arranged on the top of the casing and can be used to enter operating commands. The lighting control console encompasses a display device with at least one screen that is arranged on the top of the casing. The data for the user can be graphically displayed on the screen. The lighting control console can include a casing provided with at least one cover, which can be adjusted between a closed position and an open position, wherein the cover covers at least one extra control element arranged in or on the casing in its closed position, thereby protecting the extra control element against external influences in its closed position.

Abstract: Compositions and methods for treating or preventing a hematologic malignancy, such as AML, using an anti-alpha4 antibody are described.

Abstract: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.

Abstract: Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.

Abstract: A wafer has a cutting part filled with a connecting medium. After the wafer is cut into chips along the cutting part, two contacts on two surfaces of the chip can be connected through corresponding leading wires and the connecting medium. Thus, the chip can have a flexible layout.

Abstract: The invention relates to compounds of Formula (I), a polymorph, an enantiomer, a stereoisomer, a solvate, an N-oxide derivative, or a pharmaceutically acceptable salt thereof: Formula (I), which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.

Abstract: Various embodiments include a lighting control console for controlling a lighting system comprising wherein digital adjusting commands, which can be transferred to the lighting devices of the lighting system via data connections, are generated in the lighting control console, and wherein the lighting control console comprises at least one housing, in which the hardware components are arranged so as to be protected from external influences, and wherein the lighting control console comprises a plurality of operating elements, in particular pushbuttons, slide controls and/or rotary controls, which are arranged at the upper side of the housing and by means of which operating commands can be input, and wherein the lighting control console comprises at least one display device, at which a user interface can be displayed.